BSE: 0 | NSE: SAROJA | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Saroja Pharma Industries India Ltd is a average quality company.
The key valuation ratios of Saroja Pharma Industries India Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Saroja Pharma Industries India Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 34.6% | 33.7% | 22.1% | 14.9% | - |
| Value Creation Index ⓘ | 1.5 | 1.4 | 0.6 | 0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 36.7 | 55.6 | 50.2 | 40.7 | 41 |
| Sales YoY Gr. | - | 51.8% | -9.8% | -19% | - |
| Adj EPS ⓘ | 55.6 | 3.5 | 3.4 | 2 | 2.2 |
| YoY Gr. | - | -93.7% | -2.9% | -40.2% | - |
| BVPS (₹) ⓘ | 72 | 13.7 | 17.3 | 36.4 | 36.4 |
| Adj Net Profit ⓘ | 0.7 | 1 | 1 | 0.8 | 1 |
| Cash Flow from Ops. ⓘ | -1.1 | -3.7 | 2.2 | 1 | - |
| Debt/CF from Ops. ⓘ | -2.9 | -1.7 | 4.7 | 5.6 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 3.5% | -19% | ||||
| Adj EPS ⓘ | NA | NA | -66.8% | -40.2% | ||||
| BVPSⓘ | NA | NA | -20.3% | 110.2% | ||||
| Share Price | - | - | - | -5.7% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 77.3 | 41.5 | 22 | 8.3 | 6 |
| Op. Profit Mgn % ⓘ | 3.6 | 3.8 | 5.4 | 6.3 | NAN |
| Net Profit Mgn % ⓘ | 2 | 1.9 | 2 | 2 | 2.2 |
| Debt to Equity ⓘ | 3.2 | 1.5 | 2 | 0.4 | - |
| Working Cap Days ⓘ | 0 | 75 | 115 | 154 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 41 | 67 | 81 | 0 |
Debt to equity has declined versus last 3 years average to 0.39
Return on Equity has declined versus last 3 years average to 6.00%
Sales growth has been subdued in last 3 years 3.52%
Net Profit has been subdued in last 3 years -66.78%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.2 | - |
| TTM Sales (₹ Cr.) | 40.7 | - |
| BVPS (₹.) ⓘ | 36.4 | - |
| Reserves (₹ Cr.) ⓘ | 11 | - |
| P/BV ⓘ | 1.59 | - |
| PE ⓘ | 26.53 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 23.3 |
| Equity (₹ Cr.) | 4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Sales | 36.66 | 55.63 | 50.19 | 40.67 |
| Operating Expenses ⓘ | 35.36 | 53.53 | 47.47 | 38.11 |
| Manufacturing Costs | 1.33 | 1.86 | 1.03 | 1.67 |
| Material Costs | 32.02 | 48.50 | 44.31 | 34 |
| Employee Cost | 0.55 | 0.73 | 0.83 | 0.92 |
| Other Costs ⓘ | 1.47 | 2.44 | 1.31 | 1.52 |
| Operating Profit ⓘ | 1.30 | 2.10 | 2.72 | 2.56 |
| Operating Profit Margin (%) | 3.6% | 3.8% | 5.4% | 6.3% |
| Other Income ⓘ | 0.09 | 0.32 | 0.16 | 0.20 |
| Interest ⓘ | 0.33 | 0.80 | 1.32 | 1.45 |
| Depreciation ⓘ | 0.02 | 0.05 | 0.07 | 0.09 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1.04 | 1.58 | 1.49 | 1.21 |
| Tax ⓘ | 0.30 | 0.44 | 0.43 | 0.33 |
| Profit After Tax | 0.73 | 1.14 | 1.06 | 0.88 |
| PAT Margin (%) | 2.0% | 2.0% | 2.1% | 2.2% |
| Adjusted EPS (₹) | 56.3 | 3.9 | 3.6 | 2.2 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 0.94 | 4.03 | 5.09 | 14.64 | ||||||
| Share Capital ⓘ | 0.01 | 0.23 | 2.94 | 4.02 | ||||||
| Reserves ⓘ | 0.93 | 3.80 | 2.15 | 10.62 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 3.02 | 6.14 | 10.19 | 5.74 | ||||||
| Long Term Debt | 1.42 | 1.70 | 2.81 | 2.62 | ||||||
| Short Term Debt | 1.60 | 4.44 | 7.38 | 3.11 | ||||||
| Trade Payables | 4.15 | 5.31 | 5.86 | 5.61 | ||||||
| Others Liabilities ⓘ | 0.12 | 0.04 | 0.20 | 0.58 | ||||||
| Total Liabilities ⓘ | 8.22 | 15.51 | 21.34 | 26.56 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 0.12 | 0.42 | 2.36 | 2.75 | ||||||
| Accumulated Depreciation | 0.03 | 0.07 | 0.14 | 0.23 | ||||||
| Net Fixed Assetsⓘ | 0.09 | 0.34 | 2.22 | 2.51 | ||||||
| CWIP ⓘ | 0 | 0 | 1.79 | 6.13 | ||||||
| Investmentsⓘ | 0 | 0.04 | 0.14 | 0.20 | ||||||
| Inventories | 0.66 | 0.47 | 3.87 | 0.40 | ||||||
| Trade Receivables | 7.22 | 13.98 | 11.11 | 16.24 | ||||||
| Cash Equivalents | 0 | 0.26 | 0.36 | 0.32 | ||||||
| Others Assetsⓘ | 0.25 | 0.42 | 1.86 | 0.76 | ||||||
| Total Assets ⓘ | 8.22 | 15.51 | 21.34 | 26.56 | ||||||
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1.05 | -3.67 | 2.19 | 1.02 |
| PBT ⓘ | 1.04 | 1.58 | 1.49 | 1.21 |
| Adjustment ⓘ | 0.35 | 0.84 | 1.37 | 1.52 |
| Changes in Working Capital ⓘ | -2.13 | -5.65 | -0.25 | -1.37 |
| Tax Paid ⓘ | -0.30 | -0.44 | -0.42 | -0.33 |
| Cash Flow From Investing Activity ⓘ | -0.05 | -0.34 | -4.82 | -4.76 |
| Capex | -0.05 | -0.30 | -3.73 | -0.39 |
| Net Investments | 0 | -0.04 | -0.10 | -0.06 |
| Others ⓘ | 0 | 0 | -1 | -4.31 |
| Cash Flow From Financing Activityⓘ | 1.03 | 4.27 | 2.73 | 3.70 |
| Net Proceeds from Shares ⓘ | 0 | 1.95 | 0 | 8.68 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 1.11 | -0.19 |
| Interest Paid ⓘ | -0.33 | -0.80 | -1.32 | -1.45 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 1.36 | 3.12 | 2.94 | -3.34 |
| Net Cash Flow ⓘ | -0.07 | 0.26 | 0.10 | -0.04 |
| PARTICULARS | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 78.14 | 45.95 | 23.28 | 8.9 | ||||||
| ROCE (%) | 34.59 | 33.73 | 22.1 | 14.91 | ||||||
| Asset Turnover Ratio | 4.46 | 4.69 | 2.72 | 1.7 | ||||||
| PAT to CFO Conversion(x) | -1.44 | -3.22 | 2.07 | 1.16 | Working Capital Days | |||||
| Receivable Days | 72 | 70 | 91 | 123 | ||||||
| Inventory Days | 7 | 4 | 16 | 19 | ||||||
| Payable Days | 47 | 36 | 46 | 62 | ||||||
Saroja Pharma Industries India was originally incorporated as Private Limited, under the Companies Act, 2013 (Companies Act) in the name and style of ‘Saroja Pharma Industries India Private Limited’ on January 14, 2019 under the provisions of the Companies Act, 2013 vide Certificate of Incorporation issued by the Registrar of Companies, Mumbai, Maharashtra. Later on, company was converted into public limited company and due to the conversion, the name of the company name was changed to ‘Saroja Pharma Industries India Limited’ and a fresh Certificate of Incorporation dated April 18, 2023 was issued by the Registrar of Companies, Mumbai, Maharashtra.
The company is amongst the leading traders, exporter and suppliers of Specialty Chemicals. The offered range is widely praised for its superior effectiveness, shelf life and perfect composition. The company was incorporated with the objective of the best service deliverance in chemical trading with the best premium pharmaceutical companies in India and abroad for cost effective human and veterinary medicine. The company trade in Pharma API, Pharma Intermediates, Chemicals, Solvents used for pharmaceutical products human and veterinary medicine. The Company was formed with a mission being providing clientele specification based approved product at a competitive pricing with hassle free dispatch within India or aboard contributing to cost effectiveness in end product for human and veterinary medicine.
The product demand by its clientele is manufactured as per their specifications by its suppliers initially in sample size thereafter on clients testing and approving the order is finalized. The approved specified product is manufactured for the order quantity to be dispatched by the appropriate mode of transport within India or abroad. Since its inception, Saroja Pharma Industries India has witnessed a substantial expansion in its clientele base over the past two years. This growth has propelled the company to venture into the manufacturing of API Pharma products, for veterinary use. By broadening its product portfolio, Saroja Pharma Industries India aims to provide a comprehensive range of pharmaceutical solutions that cater to the diverse needs of its expanding customer base. This strategic move not only enhances the company's value proposition but also reinforces its commitment to delivering affordable healthcare solutions globally.
Business area of the company
The company is engaged into the business of trading of pharma products like pharma API, Pharma Intermediary and Pharma chemicals.
Products of the company
Chemical
Active Pharmaceutical Ingredient (API)
Pharma Intermediary
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
